SCHEMBL649573

SCHEMBL649573

CCCn1c(-c2ccccc2)nc(C)c1CN(Cc1ccc(C(=O)OC)cc1)Cc1ccc2c(c1)OCCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.43
GSK3A P49840 1/20 0.40
GSK3B P49841 1/20 0.40
ALDH1A1 P00352 7/20 0.39
TSHR P16473 6/20 0.39
GAA P10253 3/20 0.39
HPGD P15428 2/20 0.39
MAPT P10636 3/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
PTGES O14684 1/20 0.39
ALOX5 P09917 1/20 0.39
PPARG P37231 1/20 0.39
PPARA Q07869 1/20 0.39
POLB P06746 2/20 0.38
KDM4E B2RXH2 2/20 0.38
TP53 P04637 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
LMNA P02545 1/20 0.38
ADORA2A P29274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL651293 0.95 C5AR1 (0.49) C5AR1GSK3AGSK3BALDH1A1TSHR
SCHEMBL1913101 0.93 C5AR1 (0.42) C5AR1GSK3AGSK3BALDH1A1TSHR
SCHEMBL650864 0.92 PTGES (0.47) C5AR1ALDH1A1TSHRGAAHPGD
SCHEMBL648086 0.88 C5AR1 (0.55) C5AR1GSK3AGSK3BALDH1A1TSHR
SCHEMBL650559 0.88 C5AR1 (0.48) C5AR1GSK3AGSK3BALDH1A1TSHR
SCHEMBL651546 0.88 C5AR1 (0.48) C5AR1GSK3AGSK3BALDH1A1TSHR
SCHEMBL1913102 0.87 C5AR1 (0.52) C5AR1ALDH1A1TSHRGAAHPGD
SCHEMBL651025 0.86 C5AR1 (0.48) C5AR1GSK3AGSK3BALDH1A1TSHR
SCHEMBL648477 0.86 C5AR1 (0.46) C5AR1GSK3AGSK3BALDH1A1TSHR
SCHEMBL651054 0.86 C5AR1 (0.52) C5AR1GSK3AGSK3BALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed